Aaron P Mitchell
Overview
Explore the profile of Aaron P Mitchell including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
181
Citations
6813
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Mooghali M, Mitchell A, Skydel J, Ross J, Wallach J, Ramachandran R
BMJ Med
. 2024 Apr;
3(1):e000802.
PMID: 38596814
Objectives: To evaluate National Comprehensive Cancer Network (NCCN) guideline recommendations for oncology drug treatments that have been granted accelerated approval, and to determine whether recommendations are updated based on the...
12.
Mitchell A, Kinlaw A, Peacock-Hinton S, Dusetzina S, Winn A, Sanoff H, et al.
Oncologist
. 2024 Mar;
29(6):527-533.
PMID: 38484395
Background: Because the markups on cancer drugs vary by payor, providers' financial incentive to use high-price drugs is differential according to each patient's insurance type. We evaluated the association between...
13.
Xiong L, Goerlich K, Mitchell A
G3 (Bethesda)
. 2024 Mar;
14(5).
PMID: 38470537
Candida albicans is a prominent fungal pathogen that can infect the bloodstream and deep tissues. One key pathogenicity trait is the ability to transition between yeast and hyphal growth. Hyphae...
14.
Mitchell A, Nemirovsky D, Mishra Meza A, Chakraborty N, Persaud S, Farooki A, et al.
JCO Oncol Pract
. 2024 Jan;
20(3):393-400.
PMID: 38190588
Purpose: Bone-modifying agents (BMAs) do not prevent skeletal-related events among patients with castration-sensitive prostate cancer (CSPC), but many patients receive BMAs unnecessarily. The costs to Medicare from overuse have not...
15.
16.
Mitchell A, Dusetzina S, Mishra Meza A, Trivedi N, Bach P, Winn A
BMJ
. 2023 Oct;
383:e075512.
PMID: 37879723
Objective: To estimate the association between oncologists' receipt of payments from the pharmaceutical industry and delivery of non-recommended or low value interventions among their patients. Design: Cohort study. Setting: Fee-for-service...
17.
18.
Mitchell A, Persaud S, Palyca P, Salner A, Farooki A, Ostroff J, et al.
Prostate
. 2023 Oct;
84(2):177-184.
PMID: 37846041
Background: Guidelines recommend bone-modifying agents (BMAs) for patients with castrate-resistant prostate cancer (CRPC) and bone metastasis, but not for castrate-sensitive prostate cancer (CSPC). Physicians beliefs and practices regarding BMA therapy...
19.
Cheng Z, Stefani C, Skillman T, Klimas A, Lee A, DiBernardo E, et al.
Adv Sci (Weinh)
. 2023 Sep;
10(30):e2302249.
PMID: 37658522
Super-resolution optical imaging tools are crucial in microbiology to understand the complex structures and behavior of microorganisms such as bacteria, fungi, and viruses. However, the capabilities of these tools, particularly...
20.
Phan Q, Solis N, Cravener M, Swidergall M, Lin J, Huang M, et al.
PLoS Pathog
. 2023 Aug;
19(8):e1011579.
PMID: 37611070
Fungal invasion of the oral epithelium is central to the pathogenesis of oropharyngeal candidiasis (OPC). Candida albicans invades the oral epithelium by receptor-induced endocytosis but this process is incompletely understood....